Archer Materials (ASX: AXE) has achieved a significant milestone with its Biochip technology, unveiling an alpha prototype of a potassium sensor that meets clinical-grade accuracy standards.
This development aligns with the company's roadmap towards a beta prototype in 2026, positioning it to pursue licensing discussions with MedTech partners.
Biochip Prototype Hits Clinical Accuracy
Archer has delivered an alpha prototype of its integrated Biochip-based potassium sensor. The prototype has demonstrated accuracy within ±0.3 mM.
This level of accuracy aligns with CLIA requirements, matching earlier laboratory results.
The technology uses a minimal 10 μL blood sample. This small volume makes it suitable for convenient finger-prick testing.
The prototype successfully integrates the Biochip, microfluidics, and readout electronics into a single packaged system.
Path to Beta Prototype and Partnerships
This alpha prototype is a crucial step towards the planned beta prototype. Archer aims to complete the beta prototype development later in 2026.
This next stage will form the foundation for licensing negotiations and manufacturing partnerships with MedTech companies.
The progress significantly de-risks the technology, moving it closer to a final product.
The company has previously highlighted the strategic importance of silicon integration for its Biochip.
This focus supports scalable manufacturing and potential cost reductions, which are vital for widespread adoption and commercialisation.
Broader Technology and Financial Context
Beyond the Biochip, Archer continues its substantial research and development investment in the 12CQ quantum project.
Recent progress includes advancements in single-electron transistor (SET) architectures and the synthesis of carbon qubit material on 1-inch silicon wafers.
The company also recently announced collaborations with Emergence Quantum, CSIRO, and IMEC.
Financially, Archer reported a cash balance of A$10.3 million at the end of Q2 FY26. This position, alongside a A$2.1 million R&D tax rebate received in January 2026, provides an estimated 7.9 quarters of funding runway.
As a pre-revenue company, Archer's ongoing R&D investment and reliance on external funding and tax incentives remain key considerations for its long-term development.
Outlook for Biochip and Quantum
Archer Materials has demonstrated significant progress with its Biochip prototype, achieving critical accuracy milestones that pave the way for future commercial partnerships.
While the Biochip advances, the company also continues to make strides in its longer-term 12CQ quantum project, underpinned by a solid cash position, though ongoing funding and execution risks remain factors for investors.
